{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:45:37Z","timestamp":1785703537555,"version":"3.56.0"},"reference-count":69,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Musculoskeletal"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Giant cell arteritis (GCA) is the most common type of systemic vasculitis and predominantly affects women over the age of 50\u2009years. Clinical presentation includes cranial and ocular involvement, joint and systemic features. Diagnosis is confirmed by positive temporal artery biopsy or ultrasound or large vessel vasculitis on positron emission tomography. Treatment includes high-dose glucocorticoids (GC) and immunosuppressants. Health-related quality of life (HRQoL) can be impacted by pain, fatigue, and sight loss; glucocorticoid therapy adds further physical, psychological, and social burdens. Patient-reported outcome measures (PROMs) aim to capture the impact of disease from the patient\u2019s perspective. A range of PROMs have been used to highlight the impact of GCA. The generic 36-Item Short Form Health Survey (SF-36) has demonstrated the effectiveness of novel treatments including Tocilizumab in clinical trials, the symptom-specific Hospital Anxiety and Depression scale has demonstrated 50% of people with GCA suffer with anxiety and a third depression, and condition-specific (GCA PRO) and treatment-specific (Steroid PRO) PROMs have been developed and validated in people with GCA for clinical practice and trials. Shared decision-making (SDM) is essential in GCA management, ensuring patients understand treatment options and decisions reflect their preferences and \u201cwhat matters to them.\u201d PROMs support SDM and enhance the patient-clinician dialogue. Early evidence from use of the GCAPRO demonstrated that PROMs have helped patients explain their symptoms, providing clinicians with clearer insights into the patient\u2019s health. There is a growing role for electronic PROMs (E-PROMs) to support patient and clinician communication and facilitate effective clinical triage. Considerations about E-PROMs include potential for digital exclusion in older patients, data governance with online apps, and clinical safety (i.e., for people reporting active disease). To fully implement E-PROMS in clinical practice and gain the maximum benefit, full integration into intuitive clinical and patient systems will be required.<\/jats:p>","DOI":"10.1177\/1759720x261462666","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:45:21Z","timestamp":1785487521000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Measurement of the impact of giant cell arteritis and treatment with glucocorticoids on health-related quality of life"],"prefix":"10.1177","volume":"18","author":[{"given":"Emily","family":"Barnes","sequence":"first","affiliation":[{"name":"School of Health and Social Well-Being, University of the West of England, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Beazer","sequence":"additional","affiliation":[{"name":"Mid Yorkshire NHS Teaching Hospital Trust, Wakefield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7764-3173","authenticated-orcid":false,"given":"Mwidimi","family":"Ndosi","sequence":"additional","affiliation":[{"name":"School of Health and Social Well-Being, University of the West of England, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Mackie","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"},{"name":"Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7939-5978","authenticated-orcid":false,"given":"Joanna C.","family":"Robson","sequence":"additional","affiliation":[{"name":"B504 Rheumatology Department, Bristol Royal Infirmary, University Hospitals Bristol and Weston NHS Foundation Trust, Upper Maudlin Street, Bristol, Avon BS2 8HW, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.01.003"},{"key":"e_1_3_4_3_2","article-title":"Giant cell arteritis","volume":"365","author":"Lazarewicz K","year":"2019","unstructured":"Lazarewicz K, Watson P. Giant cell arteritis. BMJ 2019; 365: l1964.","journal-title":"BMJ"},{"issue":"21","key":"e_1_3_4_4_2","article-title":"The diagnosis and treatment of giant cell arteritis","volume":"110","author":"Ness T","year":"2013","unstructured":"Ness T, Bley TA, Schmidt WA, et al. The diagnosis and treatment of giant cell arteritis. Dtsch Arztebl Int 2013; 110(21): 376\u2013385; quiz 386.","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.111005"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02450-w"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.07.005"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex424"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213883"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v3.i6.484"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.05.002"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103716"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223429"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez664"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.06.019"},{"key":"e_1_3_4_17_2","unstructured":"OMERACT. Glucocorticoid-related adverse events working group https:\/\/omeract.org\/working-groups\/glucocorticoids\/ (2024 accessed 2026)."},{"key":"e_1_3_4_18_2","unstructured":"OMERACT. Large vessel vasculitis working group https:\/\/omeract.org\/working-groups\/large-vessel-vasculitis\/ (2026)."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2019.1618661"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291798006667"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab076"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00041327-200112000-00008"},{"issue":"1","key":"e_1_3_4_23_2","article-title":"Anxiety and depression in patients with giant cell arteritis","volume":"8","author":"Martins-Martinho J","year":"2024","unstructured":"Martins-Martinho J, Ponte A, Dourado E, et al. Anxiety and depression in patients with giant cell arteritis. Rheumatol Adv Pract 2024; 8(1): rkae013.","journal-title":"Rheumatol Adv Pract"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2025.105864"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11464"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017073"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3619-4"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1837-7"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672120901693"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.777310"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1146815"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead201"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000585"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead081"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S213964"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-017-3855-6"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.06.010"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11234"},{"issue":"4","key":"e_1_3_4_39_2","first-page":"943","article-title":"A Canadian vasculitis patient-driven survey to highlight which prednisone-related side effects matter the most","volume":"41","author":"Yardimci GK","year":"2023","unstructured":"Yardimci GK, Pagnoux C, Stewart J. A Canadian vasculitis patient-driven survey to highlight which prednisone-related side effects matter the most. Clin Exp Rheumatol 2023; 41(4): 943\u2013947.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf121"},{"key":"e_1_3_4_41_2","unstructured":"U.S. Food & Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Federal Register Silver Spring MD 2009."},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-020-01438-5"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.12968\/bjcn.2011.16.3.146"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-016-1435-y"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-007-9204-6"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.011"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2012.10.011"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.02.006"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181072"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161467"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152602"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152338"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141143"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161083"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker017"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.072157"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224946"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-089225"},{"key":"e_1_3_4_61_2","volume-title":"Shared decision-making summary guide","author":"NHS England and NHS Improvement","year":"2019","unstructured":"NHS England and NHS Improvement. Shared decision-making summary guide. London, UK: NHS England, 2019."},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-018-0061-6"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2025.118765"},{"key":"e_1_3_4_64_2","unstructured":"NHS England. The NHS long term plan https:\/\/www.england.nhs.uk\/long-term-plan\/ (2019 accessed 10 January 2026)."},{"issue":"4","key":"e_1_3_4_65_2","article-title":"Improved clinical care and capacity through an integrated electronic patient-reported outcome measure and health record system in inflammatory arthritis","volume":"9","author":"Chan A","year":"2025","unstructured":"Chan A, Rigler K, Zabbey N, et al. Improved clinical care and capacity through an integrated electronic patient-reported outcome measure and health record system in inflammatory arthritis. Rheumatol Adv Pract 2025; 9(4): rkaf101.","journal-title":"Rheumatol Adv Pract"},{"key":"e_1_3_4_66_2","unstructured":"House of Lords Library. Digital exclusion in the UK: communications and digital committee report. London https:\/\/lordslibrary.parliament.uk\/digital-exclusion-in-the-uk-communications-and-digital-committee-report\/ (2024 accessed 10 January 2026)."},{"key":"e_1_3_4_67_2","article-title":"User or patient\/human or person? Development of a practical framework for applying user-centered design to vulnerable populations for digital transformation in healthcare","volume":"11","author":"Muller A","year":"2025","unstructured":"Muller A, Schaaf J. User or patient\/human or person? Development of a practical framework for applying user-centered design to vulnerable populations for digital transformation in healthcare. Digit Health 2025; 11: 20552076251375835.","journal-title":"Digit Health"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05263-5"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0278465"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.2196\/18117"}],"container-title":["Therapeutic Advances in Musculoskeletal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X261462666","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1759720X261462666","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X261462666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:46:26Z","timestamp":1785699986000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1759720X261462666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":69,"alternative-id":["10.1177\/1759720X261462666"],"URL":"https:\/\/doi.org\/10.1177\/1759720x261462666","relation":{},"ISSN":["1759-720X","1759-7218"],"issn-type":[{"value":"1759-720X","type":"print"},{"value":"1759-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"1759720X261462666"}}